Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 20 hours agoThese safety results are in keeping with the known toxicities of Enhertu and Perjeta....
Study: Sepsis quality metrics may unfairly penalize safety-net hospitals
Center for Infectious Disease Research and Policy· 28 minutes agoResearchers found in-hospital mortality was higher at safety-net hospitals than non–safety-net...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following...
Digital Journal· 9 hours agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, presented updated clinical ...
Telemedicine study suggests antibiotic stewardship, high provider ratings can coexist
Center for Infectious Disease Research and Policy· 3 hours agoProviders at a national telemedicine practice who received antimicrobial stewardship training were...
Council Post: What Leaders Can Learn From Modern Anti-Money Laundering Techniques
Forbes· 16 hours agoAshley Stephenson is the CTO of Corero Network Security, a leading provider of DDoS protection...
Sustained bias of spatial attention in a 3 T MRI scanner - Scientific Reports
Nature· 14 hours agoWhen lying inside a MRI scanner and even in the absence of any motion, the static magnetic field of MRI scanners induces a magneto-hydrodynamic stimulation of subjects’ vestibular organ (MVS ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
Aphakic Kids' Secondary Lens Implants Pose Risks
Medscape· 16 hours agoImplantation of a secondary intraocular lens in children with aphakic eye was associated with complications, refractive errors, and suboptimal visual...
ASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant
Clinical Trials Arena via Yahoo Finance· 2 days agoAdditionally, the median PFS benefit of the SC formulation, was 6.1 months vs 4.3 months (hazard...
Hypertension, albuminuria risks are no worse for kidney donors than for non-donors: Study
Medical Xpress· 4 days agoLiving kidney donors and non-donors have similar risks for hypertension and albuminuria, according...
